A Phase 3 interventional study of co-administration of cefepime and nacubactam and co-administration of aztreonam and nacubactam in Complicated Urinary Tract Infection, Acute Pyelonephritis and Hospital-acquired Bacterial Pneumonia, sponsored by Meiji Seika Pharma Co., Ltd.. Completed at 54 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Meiji Seika Pharma Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Intraabdominal Infections with a site in China — 6 open to participants now, 6 under way, 1 of them phase 3. Intraabdominal Infections · China.
Among the 22 studies in Intraabdominal Infections with a site in China, this one is the 12th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2023, is one of 5 in phase 3, and was the 13th registered.
129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.
Browse Intraabdominal Infections studies →6 of the 22 studies in Intraabdominal Infections with a site in China are open now. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Joincare Pharmaceutical Group Industry Co., Ltd · Sites in China
Ages 18–45 · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18–100
Dongzhimen Hospital, Beijing · Sites in China
Ages 50–90
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 6 · Phase 4 5
First in 2005; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 126 is close to the median of 140 across 77 interventional studies indexed under Intraabdominal Infections.
Median enrollment 268 across the 17 interventional studies, 100 across the 5 observational. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 22 have an industry lead sponsor. The 10 most frequent:
Meiji Seika Pharma Co., Ltd. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Meiji Seika Pharma Co., Ltd. has 1 study filed under Intraabdominal Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in Intraabdominal Infections with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06633718Phase 3Qilu Pharmaceutical Co., Ltd.Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI | 2027-05-30 |
| NCT06504316RenJi HospitalOXiris for Abdominal SEptic Shock (OASES Study) | 2027-03-31 |
| NCT06304779Shanghai Zhongshan HospitalThe Effect of Continuous Intravenous Infusion of Lidocaine on PPCs and Prognosis in Emergency Surgical Patients With IAI | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies in Intraabdominal Infections with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a multi-center, randomized, single-blind, parallel-group study to assess the efficacy and safety, when nacubactam is coadministered with cefepime or aztreonam, compared with best available therapy (BAT), in the treatment of patients with cUTI, AP, HABP, VABP, and cIAI, due to Carbapenem Resistant Enterobacterales.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following criteria must be satisfied:
a. For known CRE infection, meets either of the following (i or ii): i. Has a known CRE infection, alone or as a single isolate of a polymicrobial infection, based on evidence from CRE culture, susceptibility testing, and possible carbapenemase phenotypic testing (or possible molecular testing) within 72 hours (or 96 hours for cIAI) prior to the first dose of study drug; AND Has received no more than 24 hours of an antimicrobial agent to which the known CRE is known to be susceptible within 72 hours (or 96 hours for cIAI) prior to the first dose of study drug; OR ii. Has a known CRE infection, alone or as a single isolate of a polymicrobial infection, based on evidence from CRE culture, susceptibility testing, and possible carbapenemase phenotypic testing (or possible molecular testing) within 72 hours (or 96 hours for cIAI) prior to the first dose of study drug; AND Has documented clinical evidence of failure (ie, clinical deterioration or failure to improve) after at least 48 hours of treatment with an antimicrobial agent to which the known CRE is known to be susceptible within 72 hours (or 96 hours for cIAI) prior to the first dose of study drug; b. For suspected CRE infection, meets the following (i or ii): i. Has a suspected CRE infection, alone or as a single isolate of a polymicrobial infection, based on evidence which may be determined within 90 days prior to the first dose of study drug through rapid diagnostic tests, active surveillance cultures, other documentation of CRE colonization, or prior infection due to a CRE pathogen; AND Has received no more than 24 hours of empiric antimicrobial therapy for Gram negative organisms within 72 hours (or 96 hours for cIAI) prior to the first dose of study drug; ii. Has a suspected CRE infection, alone or as a single isolate of a polymicrobial infection, based on evidence which may be determined within 90 days prior to the first dose of study drug through rapid diagnostic tests, active surveillance cultures, other documentation of CRE colonization, or prior infection due to a CRE pathogen; AND Has documented clinical evidence of failure (ie, clinical deterioration or failure to improve) after at least 48 hours of treatment with empiric antimicrobial therapy for Gram-negative organisms within 72 hours (or 96 hours for cIAI) prior to the first dose of study drug; Note: CRE is defined as Enterobacterales by susceptibility data of MIC at least 2 microg/mL to imipenem or meropenem OR imipenem or meropenem disk diffusion (zone diameter \< 22 mm). If MIC or disk diffusion data are not available in the local laboratory or before the availability of MIC or disk diffusion results, each site can use other methods and criteria in the institution (eg, phenotypic or molecular testing) as the initial evidence of CRE for enrollment. In any case, pathogen identification and susceptibility testing performed at the central laboratory will be used to determine CRE in the final study analysis.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
co-administration of 2 g cefepime and 1 g nacubactam q8h (60 min. infusion)
Drug: co-administration of cefepime and nacubactam
co-administration of 2 g aztreonam and 1g nacubactam q8h (60 min. infusion)
Drug: co-administration of aztreonam and nacubactam
Best Available Therapy
Drug: BAT
Drug pages: Cefepime · Nacubactam
2 g cefepime and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
Drug pages: Aztreonam · Nacubactam
2 g aztreonam and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
Dosage of BAT will be based per site's standard of care
The primary efficacy endpoint is the proportion of patients with overall treatment success at TOC across all infection types (ie, cUTI, AP, HABP, VABP, and cIAI), which is a composite endpoint derived from the efficacy outcomes of each infection type.
For cUTI and AP, the composite clinical outcome of cure and the microbiological outcome of eradication are defined as the outcome of cure. For HABP and VABP, the clinical success is defined as the outcome of cure. For cIAI, the clincal success is defined as the outcome of cure.
Time frame: TOC (Test of Cure visit): 7 [±2] days after EOT (end of treatment) [Day 10 to 23 after the start of treatment]
The proportion of patients with overall treatment outcome of success across all infection types
Overall treatment success was defined according to infection type. For cUTI/AP, it was defined as the composite of clinical outcome of cure and microbiological outcome of eradication. For HABP/VABP and cIAI, it was defined as clinical outcome of cure alone.
Time frame: Outcome measurements were assessed at various visits: EA (Early Assessment): Day 3 to 5 days, EOT: (End of Treatment): Day 5 to Day 14, FUP (Follow-Up visit): Day 17 to Day 30
The proportion of patients with a clinical outcome of cure per type of resistance
Assessment of clinical outcome was based on the Investigator's evaluation of the patient's clinical signs and symptoms, with cure defined as the complete resolution (or return to premorbid state) of the baseline signs and symptoms present at screening, such that no further antimicrobial therapy is warranted. For this endpoint, results were summarized per type of resistance.
Time frame: TOC (Test of Cure visit):7 [±2] days after EOT [Day 10 to 23]
The proportion of patients with a microbiological outcome of eradication per type of pathogen and per type of resistance
For cUTI/AP, microbiological outcome was determined programmatically based on quantitative microbiological urine cultures, with eradication defined as the pathogen found at screening with 10\^5 CFU/ml or more reduced to less than 10\^3 CFU/ml. For HABP/VABP and cIAI, eradication was defined as the absence of the baseline Gram-negative pathogen(s) on repeat culture, or presumed eradication, which is no culture was done and the patient meets the clinical criteria for clinical cure. The results of subgroup analyses for only the three most frequent pathogens were shown because there were a large number of pathogen types, most of which were rare and sparsely represented in the dataset.
Time frame: TOC (Test of Cure visit):7 [±2] days after EOT [Day 10 to 23]
The all-cause mortality rate at Day 28 by each infection type (ie, cUTI/AP, HABP/VABP, or cIAI) and across all infection types
The all-cause mortality rate at Day 28 was calculated as the percentage of participants who experienced mortality regardless of the cause at or before Day 28.
Time frame: Day 28 (+ 2days)
The proportion of patients with a clinical outcome of cure by each infection type (ie, cUTI/AP, HABP/VABP, or cIAI) and across all infection types
Assessment of clinical outcome was based on the Investigator's evaluation of the patient's clinical signs and symptoms, with cure defined as the complete resolution (or return to premorbid state) of the baseline signs and symptoms present at screening, such that no further antimicrobial therapy is warranted. Results were summarized by each infection type (ie, cUTI/AP, HABP/VABP, or cIAI) and across all infection types.
Time frame: TOC (Test of Cure visit):7 [±2] days after EOT [Day 10 to 23]
The proportion of patients with a microbiological outcome of eradication (including presumed eradication) by each infection type (ie, cUTI/AP, HABP/VABP, or cIAI) and across all infection types
For cUTI/AP, microbiological outcome was determined programmatically based on quantitative microbiological urine cultures, with eradication defined as the pathogen found at screening with 10\^5 CFU/ml or more reduced to less than 10\^3 CFU/ml. For HABP, VABP, and cIAI, eradication was defined as the absence of the baseline Gram-negative pathogen(s) on repeat culture, or presumed eradication, which is no culture was done and the patient meets the clinical criteria for clinical cure. Results were summarized by each infection type (ie, cUTI/AP, HABP/VABP, or cIAI) and across all infection types.
Time frame: TOC (Test of Cure visit):7 [±2] days after EOT [Day 10 to 23]
The proportion of patients with composite clinical and microbiological success for cUTI/AP patients
Composite clinical and microbiological success is defined as the composite clinical outcome of cure and the microbiological outcome of eradication. Assessment of clinical outcome was based on Investigator's evaluation of the patient's clinical signs and symptoms, with cure defined as the complete resolution (or return to premorbid state) of the baseline signs and symptoms of cUTI or AP that were present at screening, such that no further antimicrobial therapy is warranted. Microbiological outcome was determined programmatically based on quantitative microbiological urine cultures, with eradication defined as the pathogen found at screening with 10\^5 CFU/ml or more reduced to less than 10\^3 CFU/ml.
Time frame: TOC (Test of Cure visit):7 [±2] days after EOT [Day 10 to 23]
The proportion of patients with composite clinical outcome of recurrence and/or microbiological outcome of recurrence at the FUP for cUTI/AP patients
Composite clinical and microbiological success is defined as the composite clinical outcome of cure and the microbiological outcome of eradication. Assessment of clinical outcome was based on Investigator's evaluation of the patient's clinical signs and symptoms, with cure defined as the complete resolution (or return to premorbid state) of the baseline signs and symptoms of cUTI or AP that were present at screening, such that no further antimicrobial therapy is warranted. Microbiological outcome was determined programmatically based on quantitative microbiological urine cultures, with eradication defined as the pathogen found at screening with 10\^5 CFU/ml or more reduced to less than 10\^3 CFU/ml.
Time frame: FUP(Follow-Up visit):14 [±2] days after EOT [Day 17 to Day 30]
Total ventilator days measured from time of randomization to EOT for HABP/VABP patients
Total ventilator days are defined as number of days from the date of randomization to the date at which the ventilator is removed or date of end of treatment, whichever is earlier.
Time frame: EOT (End of Treatment): [Day 5 to Day 14]
Change in the partial pressure of oxygen to FiO2 ratio from baseline to EOT for HABP/VABP patients
The partial pressure oxygen to fraction of inspired oxygen ratio at baseline and EOT and change from baseline is summarized by treatment group.
Time frame: EOT (End of Treatment): [Day 5 to Day 14]
Time (days) to extubation in patients who are on the ventilator at baseline for HABP/VABP patients
Time to extubation was defined as number of days from the date of the first dose of study drug to the last date at which the ventilator was removed. Kaplan-Meier estimates were used for the analysis of time to extubation for each treatment group, and hazard ratios along with 95% CI was used to analyze time to extubation differences between treatment groups. Patients who were on the ventilator at baseline but discontinued from the study without extubation were considered censored.
Time frame: Up to EOT (End of Treatment): [Day 5 to Day 14]
The proportion of patients with clinical outcome of recurrence at the FUP for HABP/VABP patients
Clinical Outcome of Recurrence is defined as the reappearance of baseline clinical signs and symptoms at the Follow-up (FUP) visit after a prior assessment of cure.
Time frame: FUP(Follow-Up visit):14 [±2] days after EOT [Day 17 to Day 30]
The proportion of patients with clinical outcome of recurrence at the FUP for cIAI patients
Clinical Outcome of Recurrence is defined as the reappearance of baseline clinical signs and symptoms at the Follow-up (FUP) visit after a prior assessment of cure.
Time frame: FUP(Follow-Up visit):14 [±2] days after EOT [Day 17 to Day 30]
The all-cause mortality rate at Day 28 for secondary bacteremia patients
The all-cause mortality rate at Day 28 was calculated as the percentage of participants who experienced mortality regardless of the cause at or before Day 28.
Time frame: Day 28 (+ 2days)
The proportion of patients with overall treatment success across all infection types at TOC for secondary bacteremia patients
Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Overall treatment success was defined according to infection type. For cUTI/AP, it was defined as the composite of clinical outcome of cure and microbiological outcome of eradication. For HABP, VABP, and cIAI, it was defined as clinical outcome of cure alone.
Time frame: TOC (Test of Cure visit):7 [±2] days after EOT [Day 10 to 23]
The proportion of patients with a clinical outcome of cure across all infection types at TOC for secondary bacteremia patients
Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Assessment of clinical outcome was based on the Investigator's evaluation of the patient's clinical signs and symptoms, with cure defined as the complete resolution (or return to premorbid state) of the baseline signs and symptoms present at screening, such that no further antimicrobial therapy is warranted.
Time frame: TOC (Test of Cure visit):7 [±2] days after EOT [Day 10 to 23]
The proportion of patients with a microbiological outcome of eradication across all infection types at TOC for secondary bacteremia patients
Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Microbiological outcome will be determined programmatically based on blood cultures, with eradication defined as the pathogen found at screening is negative in blood culture.
Time frame: TOC (Test of Cure visit):7 [±2] days after EOT [Day 10 to 23]
The proportion of patients with a clinical outcome of cure from secondary bacteremia at TOC for secondary bacteremia patients
Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Clinical outcome of cure from secondary bacteremia is defined as complete resolution or significant improvement of the baseline signs and symptoms of secondary bacteremia.
Time frame: TOC (Test of Cure visit):7 [±2] days after EOT [Day 10 to 23]
The proportion of patients with a microbiological outcome of eradication from secondary bacteremia at TOC for secondary bacteremia patients
Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Microbiological outcome will be determined programmatically based on blood cultures, with eradication defined as the pathogen found at screening is negative in blood culture.
Time frame: TOC (Test of Cure visit):7 [±2] days after EOT [Day 10 to 23]
The proportion of patients who are free from secondary bacteremia at TOC for secondary bacteremia patients
Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Both clinical outcome and microbiological outcome were evaluated in patients with secondary bacteremia. Assessment of clinical outcome was based on signs and symptoms, with cure defined as complete resolution or significant improvement of the baseline signs and symptoms of secondary bacteremia. Microbiological outcome will be determined programmatically based on blood cultures, with eradication defined as the pathogen found at screening is negative in blood culture.
Time frame: TOC (Test of Cure visit):7 [±2] days after EOT [Day 10 to 23]
The proportion of patients free from the definition of secondary bacteremia and a clinical outcome of cure across all infection types and a microbiological outcome of eradication from all infection types at TOC for secondary bacteremia patients
Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. For assessment of cUTI/AP, HABP/VABP, cIAI is done by the same way as clinical outcome and microbiological outcome. For secondary bacteremia, assessment of clinical outcome was based on signs and symptoms, with cure defined as complete resolution or significant improvement of the baseline signs and symptoms of secondary bacteremia. Microbiological outcome will be determined programmatically based on blood cultures, with eradication defined as the pathogen found at screening is negative in blood culture.
Time frame: TOC (Test of Cure visit):7 [±2] days after EOT [Day 10 to 23]
Ran from Sep 2023 to primary completion in Sep 2025, 23 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cefepime · Nacubactam · Aztreonam
Meiji Seika Pharma Co., Ltd.